Standard Biotools (LAB) Equity Average (2011 - 2026)

Standard Biotools (LAB) has 16 years of Equity Average data on file, last reported at $492.7 million in Q1 2026.

• Quarterly Equity Average rose 6.38% year-over-year to $492.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $492.7 million (up 6.38% YoY) and the FY2025 annual result came in at $448.0 million, up 176.83% from the prior year.
• Equity Average improved to $492.7 million in Q1 2026 per LAB's latest filing, from $412.0 million in the prior quarter.
• Across five years, Equity Average topped out at $543.8 million in Q2 2024 and bottomed at -$139.9 million in Q4 2023.
• The 5-year median for Equity Average is $214.6 million (2024), against an average of $201.7 million.
• The widest annual swing landed in 2023, when Equity Average tumbled 1272.4%; it then surged 616.57% in 2024.
• Tracing LAB's Equity Average over 5 years: stood at -$72.1 million in 2022, then tumbled by 94.0% to -$139.9 million in 2023, then jumped by 443.51% to $480.5 million in 2024, then slipped by 14.27% to $412.0 million in 2025, then grew by 19.6% to $492.7 million in 2026.
• Per Business Quant, the three latest LAB Equity Average figures stand at $492.7 million (Q1 2026), $412.0 million (Q4 2025), and $412.1 million (Q3 2025).

Peer Comparison